Therapeutic agents for Alzheimer’s disease: a critical appraisal
Author Information
Author(s): Marta Weinstock
Primary Institution: Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University, Jerusalem, Israel
Conclusion
Ladostigil shows promise in reducing cognitive decline in mild cognitive impairment without significant adverse effects.
Supporting Evidence
- Ladostigil reduced the decline in short-term memory and brain volumes in subjects with mild cognitive impairment.
- Adverse effects of ladostigil were mild and comparable to placebo.
- The study included 100 subjects, with a significant difference in cognitive decline rates between treatment and placebo groups.
Takeaway
This study looks at different treatments for Alzheimer's disease and finds that a drug called ladostigil might help people with early memory problems without causing bad side effects.
Methodology
The study reviewed various therapeutic agents for Alzheimer's disease, focusing on their efficacy and safety, particularly ladostigil in a phase 2 trial.
Potential Biases
No financial support was declared, reducing potential bias.
Limitations
The study was underpowered due to a high withdrawal rate and a low conversion rate to Alzheimer's in the placebo group.
Participant Demographics
Subjects included individuals with mild cognitive impairment, with a focus on those without the ApoE4 gene.
Statistical Information
P-Value
0.028
Statistical Significance
p=0.028
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website